Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT01028222
- Locations
- 🇺🇸
Baylor Health Care System/Sammons Cancer Center Baylor 2, Dallas, Texas, United States
🇺🇸University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Case Western Reserve Case Western, Cleveland, Ohio, United States
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT01006980
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 385
- Registration Number
- NCT00936221
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
- Conditions
- Interventions
- Biological: bleomycin sulfateDrug: ABVD regimenDrug: cisplatinDrug: carmustineDrug: cytarabineDrug: dacarbazineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: gemcitabine hydrochlorideDrug: methylprednisoloneDrug: vincristine sulfateDrug: ifosfamideDrug: vindesineDrug: melphalanDrug: mitoguazoneDrug: vinorelbine tartrateProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 442
- Registration Number
- NCT00920153
- Locations
- 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 529
- Registration Number
- NCT00864253
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸Mary Crowley Research Center, Dallas, Texas, United States
🇦🇺Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00849875
- Locations
- 🇫🇷
GSK Investigational Site, Villejuif, France
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 371
- Registration Number
- NCT00822120
- Locations
- 🇺🇸
Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States
🇺🇸Illinois CancerCare - Macomb, Macomb, Illinois, United States
🇺🇸Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT00802880
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00796991
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1202
- Registration Number
- NCT00678327
- Locations
- 🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.